Table 5.
Effect of different drugs` regimens on some clinical data of the patients
| Clinical data | Group I (n=20) | Group II (n=20) | Group III (n=20) | P values |
| Weight gain (kg) | 21.83±7.52 | 25.79±9.55 | 22.42±7.75 | 0.275 |
| Blood sugar (mg/dL) | 86.00±11.89 | 80.95±9.08 | 93.45±13.95 | 0.006 |
| Eosinophilic count (%) | 6.75±4.44 | 6.15±3.86 | 6.15±3.76 | 0.863 |
| IgE level | 342.6±184.70 | 334.35±196.83 | 330.35±179.07 | 0.972 |
| PEF (%) | 80.10±0.37 | 79.95±11.32 | 80.70±10.25 | 0.973 |
| FEV1/FVC (%) | 86.30±4.61 | 88.10±4.38 | 86.90±4.22 | 0.426 |
| PRAM score | 1.35±1.09 | 1.45±1.10 | 1.35±1.14 | 0.947 |
| MPIS | 2.10±1.62 | 2.45±1.79 | 2.20±1.67 | 0.798 |
| Side effects | ||||
| Vomiting | 3 (15) | 4 (20) | 7 (35) | 0.31 |
| GIT cramps | 1 (5) | 4 (20) | 3 (15) | 0.32 |
| Relapse of symptoms | 7 (35) | 6 (30) | 4 (20) | 0.56 |
| ATAQ score after 30 days | 2.95±2.19 | 3.35±2.01 | 3.05±2.09 | 0.822 |
Data presented as mean ±SD or N (%).
ATAQ, Asthma Therapy Assessment Questionnaire; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; GIT, gastrointestinal tract; MPIS, Modified Pulmonary Index Score; PEF, peak expiratory flow; PRAM, Paediatric Respiratory Assessment Measure.